<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bohringer N</submitter><funding>HHS | National Institutes of Health</funding><funding>German Federal Ministry of Education and Research (BMBF) via a project of the Deutsche Zentrum für Infektionsforschung</funding><funding>AntiResist: New approaches to combat antibiotic-resistant bacteria</funding><funding>Swiss National Science Foundation</funding><funding>NIAID NIH HHS</funding><pagination>e0153521</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8694152</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(3)</volume><pubmed_abstract>There is great need for therapeutics against multidrug-resistant, Gram-negative bacterial pathogens. Recently, darobactin A, a novel bicyclic heptapeptide that selectively kills Gram-negative bacteria by targeting the outer membrane protein BamA, was discovered. Its efficacy was proven in animal infection models of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, thus promoting darobactin A as a promising lead compound. Originally discovered from members of the nematode-symbiotic genus &lt;i>Photorhabdus&lt;/i>, the biosynthetic gene cluster (BGC) encoding the synthesis of darobactin A can also be found in other members of the class &lt;i>Gammaproteobacteria&lt;/i>. Therein, the precursor peptides DarB to -F, which differ in their core sequence from darobactin A, were identified &lt;i</pubmed_abstract><journal>Microbiology spectrum</journal><pubmed_title>Mutasynthetic Production and Antimicrobial Characterization of Darobactin Analogs.</pubmed_title><pmcid>PMC8694152</pmcid><funding_grant_id>180541</funding_grant_id><funding_grant_id>51AU40_180541</funding_grant_id><funding_grant_id>TTU09.818</funding_grant_id><funding_grant_id>187170</funding_grant_id><funding_grant_id>R01 AI158388</funding_grant_id><funding_grant_id>R01AI158388</funding_grant_id><pubmed_authors>Modaresi SM</pubmed_authors><pubmed_authors>Lewis K</pubmed_authors><pubmed_authors>Jakob RP</pubmed_authors><pubmed_authors>Iinishi A</pubmed_authors><pubmed_authors>Mettal U</pubmed_authors><pubmed_authors>Maier T</pubmed_authors><pubmed_authors>Schaberle TF</pubmed_authors><pubmed_authors>Hiller S</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Green R</pubmed_authors><pubmed_authors>Marner M</pubmed_authors><pubmed_authors>Wuisan ZG</pubmed_authors><pubmed_authors>Bohringer N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Mutasynthetic Production and Antimicrobial Characterization of Darobactin Analogs.</name><description>There is great need for therapeutics against multidrug-resistant, Gram-negative bacterial pathogens. Recently, darobactin A, a novel bicyclic heptapeptide that selectively kills Gram-negative bacteria by targeting the outer membrane protein BamA, was discovered. Its efficacy was proven in animal infection models of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, thus promoting darobactin A as a promising lead compound. Originally discovered from members of the nematode-symbiotic genus &lt;i>Photorhabdus&lt;/i>, the biosynthetic gene cluster (BGC) encoding the synthesis of darobactin A can also be found in other members of the class &lt;i>Gammaproteobacteria&lt;/i>. Therein, the precursor peptides DarB to -F, which differ in their core sequence from darobactin A, were identified &lt;i</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2026-06-10T05:52:57.528Z</modification><creation>2025-04-05T20:40:20.511Z</creation></dates><accession>S-EPMC8694152</accession><cross_references><pubmed>34937193</pubmed><doi>10.1128/spectrum.01535-21</doi></cross_references></HashMap>